Varenicline 0.5 mg Tablet Requirements for Smoking Cessation
For patients with normal renal function: 153 tablets are needed for a 12-week regimen, and 306 tablets for a 24-week regimen (12-week initial + 12-week extension). 11
Standard Dosing Calculation (Normal Renal Function)
The FDA-approved titration schedule requires 11:
Week 1 (Titration):
- Days 1-3: 0.5 mg once daily = 3 tablets
- Days 4-7: 0.5 mg twice daily = 8 tablets
- Week 1 subtotal: 11 tablets
Weeks 2-12 (Maintenance):
- 1 mg twice daily (equivalent to 0.5 mg × 4 tablets daily)
- 11 weeks × 7 days × 4 tablets = 308 tablets
- Weeks 2-12 subtotal: 308 tablets
Total for 12-week regimen: 319 tablets of 0.5 mg
Note: If using 1 mg tablets for maintenance (standard practice), you would need 11 tablets of 0.5 mg for titration plus 154 tablets of 1 mg for maintenance.
For 24-week treatment: Patients who successfully quit after 12 weeks should receive an additional 12 weeks at 1 mg twice daily to increase long-term abstinence 11. This doubles the maintenance requirement.
Severe Renal Impairment (CrCl <30 mL/min)
For severe renal impairment: 84 tablets are needed for a 12-week regimen 11:
- Titration: 0.5 mg once daily for 3 days = 3 tablets
- Maximum dose: 0.5 mg twice daily for remainder of treatment
- Days 4-84: 0.5 mg twice daily = 162 tablets
- Total: 165 tablets of 0.5 mg for 12 weeks
The dose reduction is necessary because varenicline is almost exclusively excreted unchanged in urine, and systemic exposure increases approximately 2-fold in severe renal impairment 2.
End-Stage Renal Disease on Hemodialysis
For hemodialysis patients: 84 tablets maximum for a 12-week regimen 11:
- Maximum dose: 0.5 mg once daily if tolerated
- 12 weeks × 7 days = 84 tablets total
This conservative dosing reflects the ~2-fold increase in drug exposure and the need to minimize adverse effects in this vulnerable population 2.
Critical Dosing Considerations
Mild to moderate renal impairment (CrCl ≥30 mL/min): No dose adjustment needed; use standard dosing as above 11.
Common pitfall: The FDA label specifies that the 1 mg twice daily target dose is achieved by using two 0.5 mg tablets twice daily, not by switching to 1 mg tablets, though both approaches deliver equivalent dosing 1. Prescribers should clarify tablet strength when calculating quantities.
Extension therapy rationale: The additional 12-week course is specifically recommended for patients who successfully quit during initial treatment, as this significantly improves long-term abstinence rates 113.